‘Oral drugs can address the unmet PNH treatment needs’
By Son, Hyung Min | translator Alice Kang
24.11.26 05:18:42
가나다라
0
Novartis Korea holds conference to celebrate the approval of Fabhalta in Korea on the 25th
Unmet demand exists with C5 inhibitors...'extravasation hemolysis' is a concern
Fabhalta shows effect even in patients who failed existing treatments..."overcomes the side effect issue”
▲ Dr. Jun Ho Jang, Professor of Medicine, Department of Hematology-Oncology, Samsung Medical Center
The paroxysmal nocturnal hemoglobinuria (PNH) market, which has been dominated by AstraZeneca's Soliris and Ultomiris, has seen the introduction of the oral drug Fabhalta. Experts believe that Fabhalta’s use will increase in the future as it has been shown to reduce anemia and blood transfusions compared to existing treatments. On the 25th, Novartis Korea held a press conference for specialized journalists in Samseong-dong, Seoul, to celebrate the approval of Fabhalta in Korea. Fabhalta was approved in August as the first oral treatment for PNH.
PNH is a rare and life-threatening disease caused by the destruction of red blood cells in the blood vessels, leading to symptoms o
Son, Hyung Min(shm@dailypharm.com)
If you want to see the full article, please JOIN US (click)